{"$schema":"https://raw.githubusercontent.com/jsonresume/resume-schema/v1.0.0/schema.json","awards":[{"awarder":"Fred Hutchinson Cancer Center","date":"2016 – 2018","title":"Joel Meyers Endowment Fellow"},{"awarder":"ID Week — Infectious Diseases Society of America","date":"2016","title":"Best Abstract Award"},{"awarder":"Harborview Medical Center, Seattle","date":"2015","title":"Consultant of the Month"},{"awarder":"ARC","date":"2005","title":"ARC Fellow \u0026 Keynote Speaker"},{"awarder":"Biomedical Engineering Honor Society","date":"2001","title":"Inductee — Alpha Eta Mu Beta"},{"awarder":"Engineering Honor Society","date":"2001","title":"Inductee — Tau Beta Pi"}],"basics":{"email":"jonathan@golob.org","label":"Director, AI/ML — Vaccines \u0026 Infectious Disease, GSK","location":{"city":"Seattle","countryCode":"US","region":"WA"},"name":"Jonathan L. Golob, MD, PhD","phone":"1-206-992-0428","profiles":[{"network":"github.com/jgolob","url":"https://github.com/jgolob"},{"network":"in/jonathan-golob","url":"https://www.linkedin.com/in/jonathan-golob/"},{"network":"Google Scholar","url":"https://scholar.google.com/citations?user=y0uGVz0AAAAJ"},{"network":"ORCID","url":"https://orcid.org/0000-0003-0009-5815"},{"network":"@golob","url":"https://twitter.com/golob"}],"summary":"As a computational biologist and physician, I apply AI/ML to enhance human health and accelerate drug and vaccine development. With training in computer science, biomedical engineering, and nearly three decades in biomedical research — including frontline transplant–infectious-disease medicine — I build robust, reproducible, and inclusive tools for healthcare and lead the teams that ship them.","url":"https://golob.org/"},"education":[{"area":"","institution":"Fred Hutchinson Cancer Center","studyType":"Transplant Infectious Diseases Fellowship"},{"area":"","institution":"University of Washington","studyType":"Infectious Diseases Fellowship"},{"area":"","institution":"University of Washington","studyType":"Internal Medicine Residency"},{"area":"PhD, Pathology (stem-cell epigenetics)","institution":"University of Washington","studyType":"MD–PhD — Medical Scientist Training Program"},{"area":"","institution":"Johns Hopkins University","studyType":"BS — Biomedical Engineering \u0026 Computer Science (dual degree)"}],"meta":{"canonical":"https://golob.org/resume.json","lastModified":"2026-06-20"},"projects":[{"description":"Building on MaLiAmPi, an atlas of the human microbiome in health and disease — harmonizing new raw data into existing feature sets, a key step toward clinical translation of microbiome-based predictive models like those from the preterm-birth DREAM challenge.","name":"The Human Microbiome Atlas"},{"description":"Led a crowdsourced machine-learning challenge to identify pregnancies at high risk of early preterm birth from vaginal-microbiome data, validated on independent datasets harmonized post-hoc. With Marina Sirota and Tomiko Oskotsky.","name":"March of Dimes Preterm-Birth Prediction DREAM Challenge"},{"description":"Identified the clinical relevance of microbiome butyrate production inhibiting gut recovery after injury during hematopoietic stem cell transplant — combining human observational data with organoid-based in vitro modeling — and latent HHV-7 infection of epithelium as a modulator of host–microbiome interactions.","name":"Microbiome \u0026 outcomes in bone-marrow transplant"},{"description":"Decoding the meaning of genetic variation — especially \u0026ldquo;variants of unknown significance\u0026rdquo; — for a general audience, with Ranjani Ramamurthy.","name":"Decoding the genetic jigsaw"}],"publications":[{"name":"Developing a multi-domain EHR foundation model for predicting Hepatitis B liver disease: a clinical perspective, 2026. doi: 10.64898/2026.01.23.26344677","releaseDate":"2026","topic":"AI / ML for biomedicine","url":"https://doi.org/10.64898/2026.01.23.26344677"},{"name":"ViroGym: Realistic Large-Scale Benchmarks for Evaluating Viral Proteins, ArXiv.org, 2026.","releaseDate":"2026","topic":"Virology \u0026 vaccinology"},{"name":"Expanding vaginal microbiome pangenomes via a custom MIDAS database reveals Lactobacillus crispatus accessory genes associated with cervical dysplasia, mSystems, 2026. doi: 10.1128/msystems.01498-25","releaseDate":"2026","topic":"Perinatal \u0026 women's health","url":"https://doi.org/10.1128/msystems.01498-25"},{"name":"Vaginal microbiome structure in pregnancy and host factors predict preterm birth: Results from the ECHO Cohort, Annals of Epidemiology, 2025. doi: 10.1016/j.annepidem.2025.11.003","releaseDate":"2025","topic":"Perinatal \u0026 women's health","url":"https://doi.org/10.1016/j.annepidem.2025.11.003"},{"name":"IL-15 Promotes Inflammatory Th17 Cells in the Intestine, Inflammatory Bowel Diseases, 2025. doi: 10.1093/ibd/izaf222","releaseDate":"2025","topic":"Other","url":"https://doi.org/10.1093/ibd/izaf222"},{"name":"J. Hédou et al., “Discovery of sparse, reliable omic biomarkers with Stabl,” Nat Biotechnol, Jan. 2024, doi: 10.1038/s41587-023-02033-x","releaseDate":"2024","topic":"AI / ML for biomedicine","url":"https://doi.org/10.1038/s41587-023-02033-x"},{"name":"Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases, mBio, 2024. doi: 10.1128/mbio.01506-24","releaseDate":"2024","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1128/mbio.01506-24"},{"name":"Acarbose Impairs GutBacteroidesGrowth by Targeting Intracellular GH97 Enzymes, 2024. doi: 10.1101/2024.05.20.595031","releaseDate":"2024","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1101/2024.05.20.595031"},{"name":"Inflammation-Induced Th17 Cells Synergize with the Inflammation-Trained Microbiota to Mediate Host Resiliency Against Intestinal Injury, Inflammatory Bowel Diseases, 2024. doi: 10.1093/ibd/izae293","releaseDate":"2024","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1093/ibd/izae293"},{"name":"Tu1777 QUIESCENT CROHN’S DISEASE PATIENTS WITH PERSISTENT SYMPTOMS SHOW ENRICHMENT OF SULFUR METABOLITES AND SULFUR METABOLIC PATHWAYS, Gastroenterology, 2024. doi: 10.1016/s0016-5085(24)03714-4","releaseDate":"2024","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1016/s0016-5085(24)03714-4"},{"name":"Why Symptoms Linger in Quiescent Crohn’s Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways, Inflammatory Bowel Diseases, 2024. doi: 10.1093/ibd/izae238","releaseDate":"2024","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1093/ibd/izae238"},{"name":"Host factors are associated with vaginal microbiome structure in pregnancy in the ECHO Cohort Consortium, Scientific Reports, 2024. doi: 10.1038/s41598-024-62537-7","releaseDate":"2024","topic":"Perinatal \u0026 women's health","url":"https://doi.org/10.1038/s41598-024-62537-7"},{"name":"VMAP: Vaginal Microbiome Atlas during Pregnancy, JAMIA Open, 2024. doi: 10.1093/jamiaopen/ooae099","releaseDate":"2024","topic":"Perinatal \u0026 women's health","url":"https://doi.org/10.1093/jamiaopen/ooae099"},{"name":"J. L. Golob et al., “Microbiome preterm birth DREAM challenge: Crowdsourcing machine learning approaches to advance preterm birth research,” Cell Rep Med, p. 101350, Dec. 2023, doi: 10.1016/j.xcrm.2023.101350","releaseDate":"2023","topic":"AI / ML for biomedicine","url":"https://doi.org/10.1016/j.xcrm.2023.101350"},{"name":"Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation, Nature Medicine, 2023. doi: 10.1038/s41591-023-02587-y","releaseDate":"2023","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1038/s41591-023-02587-y"},{"name":"J. Golob et al., “The Microbiome in Quiescent Crohn’s Disease with Persistent Symptoms Show Disruptions in Microbial Sulfur and Tryptophan Pathways,” Gastro Hep Advances, Nov. 2023, doi: 10.1016/j.gastha.2023.11.005","releaseDate":"2023","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1016/j.gastha.2023.11.005"},{"name":"J. L. Golob, “Human Microbiomes and Disease for the Biomedical Data Scientist,” Annu Rev Biomed Data Sci, vol. 6, pp. 259–273, Aug. 2023, doi: 10.1146/annurev-biodatasci-020722-043017","releaseDate":"2023","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1146/annurev-biodatasci-020722-043017"},{"name":"Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study, Blood, 2023. doi: 10.1182/blood-2023-181260","releaseDate":"2023","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1182/blood-2023-181260"},{"name":"The Fecal Microbiome in Quiescent Crohn’s Disease with Persistent Gastrointestinal Symptoms Show Enrichment of Oral Microbes But Depletion of Butyrate and Indole Producers, 2023. doi: 10.1101/2023.05.16.23290065","releaseDate":"2023","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1101/2023.05.16.23290065"},{"name":"Tu1881 THE MICROBIOME IN QUIESCENT CROHN’S DISEASE PATIENTS WITH PERSISTENT SYMPTOMS IS SIMILAR TO ACTIVE CROHN’S DISEASE BUT SIGNIFICANTLY DIFFERENT FROM QUIESCENT CROHN’S DISEASE PATIENTS WITHOUT SYMPTOMS, Gastroenterology, 2023. doi: 10.1016/s0016-5085(23)03650-8","releaseDate":"2023","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1016/s0016-5085(23)03650-8"},{"name":"S. S. Minot et al., “MaLiAmPi enables generalizable and taxonomy-independent microbiome features from technically diverse 16S-based microbiome studies,” Cell Reports Methods, p. 100639, Nov. 2023, doi: 10.1016/j.crmeth.2023.100639","releaseDate":"2023","topic":"Computational methods \u0026 open-source tools","url":"https://doi.org/10.1016/j.crmeth.2023.100639"},{"name":"C. Ogimi et al., “Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant,” Bone Marrow Transplant, Sep. 2022, doi: 10.1038/s41409-022-01790-8","releaseDate":"2022","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1038/s41409-022-01790-8"},{"name":"Latent HHV7 Infection Attenuates Beneficial Host-Microbe Interactions in the Human Gut, Open Forum Infectious Diseases, 2022. doi: 10.1093/ofid/ofac492.560","releaseDate":"2022","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1093/ofid/ofac492.560"},{"name":"K. Sugihara et al., “Mucolytic bacteria license pathobionts to acquire host-derived nutrients during dietary nutrient restriction,” Cell Rep, vol. 40, no. 3, p. 111093, Jul. 2022, doi: 10.1016/j.celrep.2022.111093","releaseDate":"2022","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1016/j.celrep.2022.111093"},{"name":"M. J. Pianko and J. L. Golob, “Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation,” Cancer Metastasis Rev, vol. 41, no. 2, pp. 367–382, Jun. 2022, doi: 10.1007/s10555-022-10033-7","releaseDate":"2022","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1007/s10555-022-10033-7"},{"name":"M. E. Bowdish et al., “A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19,” Am J Respir Crit Care Med, Sep. 2022, doi: 10.1164/rccm.202201-0157OC","releaseDate":"2022","topic":"COVID-19 \u0026 pandemic response","url":"https://doi.org/10.1164/rccm.202201-0157oc"},{"name":"Immunocompromised people make up nearly half of COVID-19 breakthrough hospitalizations – an extra vaccine dose may help, 2021. doi: 10.64628/aai.yydnqsdxc","releaseDate":"2021","topic":"Virology \u0026 vaccinology","url":"https://doi.org/10.64628/aai.yydnqsdxc"},{"name":"J. L. Golob, N. Lugogo, A. S. Lauring, and A. S. Lok, “SARS-CoV-2 vaccines: a triumph of science and collaboration,” JCI Insight, vol. 6, no. 9, p. 149187, May 2021, doi: 10.1172/jci.insight.149187","releaseDate":"2021","topic":"Virology \u0026 vaccinology","url":"https://doi.org/10.1172/jci.insight.149187"},{"name":"R. J. Cieza, J. L. Golob, J. A. Colacino, and C. E. Wobus, “Comparative Analysis of Public RNA-Sequencing Data from Human Intestinal Enteroids Infected with Enteric RNA Viruses,” Viruses, vol. 13, no. 6, p. 1059, Jun. 2021, doi: 10.3390/v13061059","releaseDate":"2021","topic":"Virology \u0026 vaccinology","url":"https://doi.org/10.3390/v13061059"},{"name":"E. R. Duke et al., “Cytomegalovirus viral load kinetics as surrogate endpoints after allogeneic transplantation,” J Clin Invest, vol. 131, no. 1, Jan. 2021, doi: 10.1172/JCI133960","releaseDate":"2021","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1172/jci133960"},{"name":"P. Sharma et al., “COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-control Study,” Transplantation, vol. 105, no. 1, pp. 128–137, Jan. 2021, doi: 10.1097/TP.0000000000003447","releaseDate":"2021","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1097/tp.0000000000003447"},{"name":"A. E. Chang, J. L. Golob, T. M. Schmidt, D. C. Peltier, C. D. Lao, and M. Tewari, “Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer,” Trends Cancer, Mar. 2021, doi: 10.1016/j.trecan.2021.02.005","releaseDate":"2021","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1016/j.trecan.2021.02.005"},{"name":"E. J. Dela Cruz et al., “Genetic Variation in Toll-Like Receptor 5 and Colonization with Flagellated Bacterial Vaginosis-Associated Bacteria,” Infect Immun, vol. 89, no. 3, Feb. 2021, doi: 10.1128/IAI.00060-20","releaseDate":"2021","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1128/iai.00060-20"},{"name":"J. Imai et al., “A potential pathogenic association between periodontal disease and Crohn’s disease,” JCI Insight, vol. 6, no. 23, p. e148543, Dec. 2021, doi: 10.1172/jci.insight.148543","releaseDate":"2021","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1172/jci.insight.148543"},{"name":"Novel, Gene-Level Associations between the Microbiome and MAIT or Treg Reconstitution after Allogeneic HSCT, Transplantation and Cellular Therapy, 2021. doi: 10.1016/s2666-6367(21)00120-2","releaseDate":"2021","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1016/s2666-6367(21)00120-2"},{"name":"J. L. Golob and K. Rao, “Signal vs. noise: how to analyze the microbiome and make progress on antimicrobial resistance,” J Infect Dis, Apr. 2021, doi: 10.1093/infdis/jiab184","releaseDate":"2021","topic":"Computational methods \u0026 open-source tools","url":"https://doi.org/10.1093/infdis/jiab184"},{"name":"S. S. Minot, K. C. Barry, C. Kasman, J. L. Golob, and A. D. Willis, “geneshot: gene-level metagenomics identifies genome islands associated with immunotherapy response,” Genome Biol, vol. 22, no. 1, p. 135, May 2021, doi: 10.1186/s13059-021-02355-6","releaseDate":"2021","topic":"Computational methods \u0026 open-source tools","url":"https://doi.org/10.1186/s13059-021-02355-6"},{"name":"C. A. Goldstein et al., “The prevalence and impact of pre-existing sleep disorder diagnoses and objective sleep parameters in patients hospitalized for COVID-19,” J Clin Sleep Med, Feb. 2021, doi: 10.5664/jcsm.9132","releaseDate":"2021","topic":"COVID-19 \u0026 pandemic response","url":"https://doi.org/10.5664/jcsm.9132"},{"name":"What Types of Antibiotic Exposure Associates with Increased Risk of Respiratory Viral Disease Progression in Allogeneic Hematopoietic Cell Transplant Recipients?, Biology of Blood and Marrow Transplantation, 2020. doi: 10.1016/j.bbmt.2019.12.355","releaseDate":"2020","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1016/j.bbmt.2019.12.355"},{"name":"Organoid-derived adult human colonic epithelium responds to co-culture with a probiotic strain ofBifidobacterium longum, 2020. doi: 10.1101/2020.07.16.207852","releaseDate":"2020","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1101/2020.07.16.207852"},{"name":"J. L. Golob and S. S. Minot, “In silico benchmarking of metagenomic tools for coding sequence detection reveals the limits of sensitivity and precision,” BMC Bioinformatics, vol. 21, no. 1, p. 459, Oct. 2020, doi: 10.1186/s12859-020-03802-0","releaseDate":"2020","topic":"Computational methods \u0026 open-source tools","url":"https://doi.org/10.1186/s12859-020-03802-0"},{"name":"E. C. Somers et al., “Tocilizumab for treatment of mechanically ventilated patients with COVID-19,” Clinical Infectious Diseases, p. ciaa954, Jul. 2020, doi: 10.1093/cid/ciaa954","releaseDate":"2020","topic":"COVID-19 \u0026 pandemic response","url":"https://doi.org/10.1093/cid/ciaa954"},{"name":"The Impact of Prophylactic Systemic Antibiotics (PSA) on Cytomegalovirus (CMV) Infection: A Post-hoc Analysis of a Randomized Controlled Trial (RCT) in Hematopoietic Cell Transplantation (HCT) Recipients, Open Forum Infectious Diseases, 2019. doi: 10.1093/ofid/ofz360.1614","releaseDate":"2019","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1093/ofid/ofz360.1614"},{"name":"Butyrogenic Bacteria After Acute Graft vs. Host Disease Associate with the Development of Steroid Refractory GVHD, Open Forum Infectious Diseases, 2019. doi: 10.1093/ofid/ofz359.149","releaseDate":"2019","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1093/ofid/ofz359.149"},{"name":"J. L. Golob et al., “Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD,” Blood Adv, vol. 3, no. 19, pp. 2866–2869, Oct. 2019, doi: 10.1182/bloodadvances.2019000362","releaseDate":"2019","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1182/bloodadvances.2019000362"},{"name":"Vancomycin Is Frequently Administered to Hematopoietic Cell Transplant Recipients Without a Provider Documented Indication and Correlates with Microbiome Disruption and Adverse Events, Open Forum Infectious Diseases, 2018. doi: 10.1093/ofid/ofy210.623","releaseDate":"2018","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1093/ofid/ofy210.623"},{"name":"Antibiotic Exposure Prior to Respiratory Viral Infection is Associated with Disease Progression to Lower Respiratory Tract Infection in Allogeneic Hematopoietic Cell Transplantation Recipients, Biology of Blood and Marrow Transplantation, 2018. doi: 10.1016/j.bbmt.2017.12.461","releaseDate":"2018","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1016/j.bbmt.2017.12.461"},{"name":"C. Ogimi et al., “Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients,” Biol. Blood Marrow Transplant., vol. 24, no. 11, pp. 2293–2301, 2018, doi: 10.1016/j.bbmt.2018.05.016","releaseDate":"2018","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1016/j.bbmt.2018.05.016"},{"name":"Outcome of Hematopoietic Cell Transplantation (HCT) in Patients with Invasive Fungal Infection before HCT Without Regression or Stabilization of Radiographic Signs, Biology of Blood and Marrow Transplantation, 2018. doi: 10.1016/j.bbmt.2017.12.489","releaseDate":"2018","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1016/j.bbmt.2017.12.489"},{"name":"T. J. MacAllister, Z. Stednick, J. L. Golob, M.-L. Huang, and S. A. Pergam, “Underutilization of norovirus testing in hematopoietic cell transplant recipients at a large cancer center,” Am J Infect Control, vol. 46, no. 1, pp. 100–102, Jan. 2018, doi: 10.1016/j.ajic.2017.06.010","releaseDate":"2018","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1016/j.ajic.2017.06.010"},{"name":"Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant, Biology of Blood and Marrow Transplantation, 2018. doi: 10.1016/j.bbmt.2017.12.006","releaseDate":"2018","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1016/j.bbmt.2017.12.006"},{"name":"Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation, Blood, 2018. doi: 10.1182/blood-2018-99-115158","releaseDate":"2018","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1182/blood-2018-99-115158"},{"name":"J. L. Golob et al., “HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients,” AIDS, vol. 32, no. 15, pp. 2113–2118, Sep. 2018, doi: 10.1097/QAD.0000000000001948","releaseDate":"2018","topic":"HIV \u0026 viral persistence","url":"https://doi.org/10.1097/qad.0000000000001948"},{"name":"A. Bhattacharyya et al., “Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation,” Biol. Blood Marrow Transplant., Oct. 2017, doi: 10.1016/j.bbmt.2017.10.003","releaseDate":"2017","topic":"Transplant \u0026 immunocompromised-host infectious disease","url":"https://doi.org/10.1016/j.bbmt.2017.10.003"},{"name":"J. L. Golob et al., “Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation,” Clin. Infect. Dis., vol. 65, no. 12, pp. 1984–1991, Nov. 2017, doi: 10.1093/cid/cix699","releaseDate":"2017","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1093/cid/cix699"},{"name":"J. L. Golob, E. Margolis, N. G. Hoffman, and D. N. Fredricks, “Evaluating the accuracy of amplicon-based microbiome computational pipelines on simulated human gut microbial communities,” BMC Bioinformatics, vol. 18, no. 1, p. 283, May 2017, doi: 10.1186/s12859-017-1690-0","releaseDate":"2017","topic":"Computational methods \u0026 open-source tools","url":"https://doi.org/10.1186/s12859-017-1690-0"},{"name":"HIV Reservoir Size and Decay in 114 Individuals with Suppressed Plasma Virus for at Least Seven Years: Correlation with Age and Not ARV Regimen, IDWeek 2016, 2016.","releaseDate":"2016","topic":"HIV \u0026 viral persistence"},{"name":"Human Immunodeficiency Virus (HIV) Reservoir Size and Decay in 114 Individuals With Suppressed Plasma Virus for at Least Seven Years: Correlation With Age and Not Antiretroviral (ARV) Regimen, Open Forum Infectious Diseases, 2016. doi: 10.1093/ofid/ofw194.93","releaseDate":"2016","topic":"HIV \u0026 viral persistence","url":"https://doi.org/10.1093/ofid/ofw194.93"},{"name":"Gut Microbiome Changes in Response to Protocolized Antibiotic Administration During Hematopoietic Cell Transplantation, Open Forum Infectious Diseases, 2015. doi: 10.1093/ofid/ofv131.73","releaseDate":"2015","topic":"Microbiome \u0026 host–microbe interactions","url":"https://doi.org/10.1093/ofid/ofv131.73"},{"name":"J. L. Golob et al., “Evidence that gene activation and silencing during stem cell differentiation requires a transcriptionally paused intermediate state,” PLoS ONE, vol. 6, no. 8, p. e22416, 2011, doi: 10.1371/journal.pone.0022416","releaseDate":"2011","topic":"Other","url":"https://doi.org/10.1371/journal.pone.0022416"},{"name":"J. L. Golob, S. L. Paige, V. Muskheli, L. Pabon, and C. E. Murry, “Chromatin remodeling during mouse and human embryonic stem cell differentiation,” Dev. Dyn., vol. 237, no. 5, pp. 1389–1398, May 2008, doi: 10.1002/dvdy.21545","releaseDate":"2008","topic":"Other","url":"https://doi.org/10.1002/dvdy.21545"},{"name":"S. Ueno et al., “Biphasic role for Wnt/β-catenin signaling in cardiac specification in zebrafish and embryonic stem cells,” Proc. Natl. Acad. Sci. U.S.A., vol. 104, no. 23, pp. 9685–9690, Jun. 2007, doi: 10.1073/pnas.0702859104","releaseDate":"2007","topic":"Other","url":"https://doi.org/10.1073/pnas.0702859104"},{"name":"T. E. Boursalian, J. Golob, D. M. Soper, C. J. Cooper, and P. J. Fink, “Continued maturation of thymic emigrants in the periphery,” Nat. Immunol., vol. 5, no. 4, pp. 418–425, Apr. 2004, doi: 10.1038/ni1049","releaseDate":"2004","topic":"Other","url":"https://doi.org/10.1038/ni1049"},{"name":"Y. Cui, J. Golob, E. Kelleher, Z. Ye, D. Pardoll, and L. Cheng, “Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells,” Blood, vol. 99, no. 2, pp. 399–408, Jan. 2002, doi: 10.1182/blood.v99.2.399","releaseDate":"2002","topic":"Other","url":"https://doi.org/10.1182/blood.v99.2.399"},{"name":"Z. Gao, J. Golob, V. M. Tanavde, C. I. Civin, R. G. Hawley, and L. Cheng, “High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector,” Stem Cells, vol. 19, no. 3, pp. 247–259, 2001, doi: 10.1634/stemcells.19-3-247","releaseDate":"2001","topic":"Other","url":"https://doi.org/10.1634/stemcells.19-3-247"},{"name":"Specific transgene expression in antigen presenting cells derived from lentivirally transduced hematopoietic stem/progenitor cells, Experimental Hematology, 2000. doi: 10.1016/s0301-472x(00)00283-6","releaseDate":"2000","topic":"Other","url":"https://doi.org/10.1016/s0301-472x(00)00283-6"}],"skills":[{"keywords":["Deep learning \u0026 predictive modeling","LLMs and protein / representation models","scikit-learn, TensorFlow, PyTorch","EHR and multi-omics data","pandas, NumPy, statsmodels"],"name":"AI / Machine learning"},{"keywords":["Python (data science \u0026 Django backend)","JavaScript / D3.js data visualization","Reproducible workflows: Nextflow; Slurm / PBS / SGE","SQL \u0026 NoSQL data modeling","C / C++ / R","Leading \u0026 delivering complex software systems"],"name":"Software engineering"},{"keywords":["Engineering management \u0026 mentorship","Cross-functional, interdisciplinary delivery","Project \u0026 program management","Technical strategy \u0026 communication"],"name":"Engineering leadership"},{"keywords":["Responsible AI and AI governance","Clinical AI safety and model evaluation","Deep learning for biodefense","Detection of anomalous AI use in health and biology","Sociotechnical risk in high-stakes systems"],"name":"Responsible AI"},{"keywords":["Preclinical R\u0026D (vaccines \u0026 infectious disease)","Early-phase protocol development","Trial biomarker analysis","Site PI \u0026 trial organizing committees","Antimicrobial resistance (AMR)"],"name":"Drug \u0026 vaccine development"},{"keywords":["Microbiome, single-cell \u0026 multi-omics integration","Bioinformatics pipeline development","Gene-therapy vector design (adeno-, lenti-, AAV)","Vaccinology \u0026 epitope selection","Organoid / in vitro modeling"],"name":"Computational \u0026 translational biology"},{"keywords":["Transplant infectious disease","Immunocompromised-host \u0026 oncology infections","Internal medicine","Pandemic critical care"],"name":"Clinical"}],"work":[{"name":"GSK · R\u0026D · AI/ML","position":"Director, AI/ML — Vaccines \u0026 Infectious Disease","summary":"I lead an engineering team within the Biomedical AI group in R\u0026amp;D at GSK, applying cutting-edge AI/ML to accelerate drug and vaccine development for infectious diseases.\nEngineer — build robustly engineered products supporting R\u0026amp;D and clinical development across GSK. Engineering manager — lead a team of senior and junior engineers, focused on growth, reliability, and maintainability. Subject-matter expert — clinical-trial design and implementation, EHR data, vaccines, antimicrobials, microbiome science, and antimicrobial resistance. Scientific leadership — a leader in the Fleming Initiative, tackling antimicrobial resistance with advanced AI."},{"name":"University of Michigan · Internal Medicine / Infectious Diseases","position":"Assistant Professor","summary":"I led a research group focused on the practical clinical translation of microbiome science to patients within precision medicine — pairing novel computational techniques with cutting-edge in vitro and in vivo models — and responded to the COVID-19 pandemic, caring for hundreds of critically ill patients while developing and running human observational and interventional trials.\nComputational biologist — multi-omics integration, massive multi-study datasets, and novel approaches and workflows; team leader and individual contributor. Human clinical trialist — observational trial development, novel therapeutic and target development, protocol writing, safety monitoring, and implementation. Clinical care — transplant infectious disease; cancer, solid-organ and hematopoietic stem cell transplant. Translational research — inflammatory bowel disease, stem cell transplant, immunotherapy, and prematurity / birth outcomes. Basic research — microbe–microbe and host–microbe interaction modeling; stem-cell biology and organoids."},{"name":"Fred Hutchinson Cancer Center / University of Washington","position":"Senior Fellow · Joel Meyers Endowment Fellow","summary":"Postdoctoral fellow studying how the gut microbiome relates to and mechanistically contributes to outcomes in patients undergoing hematopoietic stem cell transplant. Mentor: David Fredricks.\nCombined human observational study data with novel analytic and computational techniques. Attending physician specializing in cancer-related infections."},{"name":"University of Washington · Department of Pathology","position":"Doctoral Researcher (MD–PhD)","summary":"My doctoral work used the (then-new) pluripotent stem-cell model to establish the basic epigenetic mechanisms behind the earliest stages of human development. I employed some of the earliest \u0026ldquo;next-generation\u0026rdquo; high-throughput sequencing and built a novel computational pipeline integrating transcriptional micro-array and tiling-array data. Mentor: Charles \u0026ldquo;Chuck\u0026rdquo; Murry."}]}